PI3Ka/Di

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Data not yet available

No registered interventional trial or approval record places this drug in the pipeline yet.

Curated evidence

Clinical evidence (9)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–9 of 9 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
PIK3CA E542K2
PI3Ka/Di	HER2-Positive Breast Carcinoma

Clinical trials

Trials with this intervention (0)

Data not yet available

No registered study lists this drug as an intervention yet.

PIK3CA E545K2
PI3Ka/Di	HER2-Positive Breast CarcinomaALIAS	Predictive	D	Supports Sensitivity Response	1	accepted	EID8017 As part of a preclinical study, the efficacy of PI3KA/Di—a selective inhibitor for the α (IC50 for p100α: 3nM) and δ (IC50 for p100δ: 20nM) subunits of class I PI3K—was evaluated for several cell line… (full text at CIViC) PMID 20453058 · O'Brien et al., 2010 · Open in CIViC	civic
〃	Malignant Breast Neoplasm	Predictive	D	Supports Sensitivity Response	1	accepted	EID8018 As part of a preclinical study, the efficacy of PI3KA/Di—a selective inhibitor for the α (IC50 for p100α: 3nM) and δ (IC50 for p100δ: 20nM) subunits of class I PI3K—was evaluated for several cell line… (full text at CIViC) PMID 20453058 · O'Brien et al., 2010 · Open in CIViC	civic

PIK3CA K111N1
PI3Ka/Di	HER2-Positive Breast CarcinomaALIAS	Predictive	D	Supports Sensitivity Response	1	accepted	EID8020 As part of a preclinical study, the efficacy of PI3KA/Di—a selective inhibitor for the α and δ subunits of class I PI3K—was evaluated for several cell lines of breast cancer. Sensitivity and resistanc… (full text at CIViC) PMID 20453058 · O'Brien et al., 2010 · Open in CIViC	civic

PTEN Loss2
PI3Ka/Di	HER2-Positive Breast CarcinomaALIAS	Predictive	D	Supports Resistance	1	accepted	EID8022 As part of a preclinical study, the efficacy of PI3KA/Di—a selective inhibitor for the α and δ subunits of class I PI3K—was evaluated for several cell lines of breast cancer. Sensitivity and resistanc… (full text at CIViC) PMID 20453058 · O'Brien et al., 2010 · Open in CIViC	civic
〃	Malignant Breast Neoplasm	Predictive	D	Supports Resistance	1	submitted	EID8021 As part of a preclinical study, the efficacy of PI3KA/Di—a selective inhibitor for the α and δ subunits of class I PI3K—was evaluated for several cell lines of breast cancer. Sensitivity and resistanc… (full text at CIViC) PMID 20453058 · O'Brien et al., 2010 · Open in CIViC	civic

ERBB2 Amplification1
PI3Ka/Di	Malignant Breast Neoplasm	Predictive	D	Does Not Support Sensitivity Response	1	submitted	EID8023 As part of a preclinical study, the efficacy of PI3KA/Di—a selective inhibitor for the α and δ subunits of class I PI3K—was evaluated for several cell lines of breast cancer. Sensitivity and resistanc… (full text at CIViC) PMID 20453058 · O'Brien et al., 2010 · Open in CIViC	civic

PIK3CA H1047L1
PI3Ka/Di	Malignant Breast Neoplasm	Predictive	D	Supports Sensitivity Response	1	accepted	EID8019 As part of a preclinical study, the efficacy of PI3KA/Di—a selective inhibitor for the α and δ subunits of class I PI3K—was evaluated for several cell lines of breast cancer. Sensitivity and resistanc… (full text at CIViC) PMID 20453058 · O'Brien et al., 2010 · Open in CIViC	civic